Meropenem - Generic Drug Details
✉ Email this page to a colleague
What are the generic sources for meropenem and what is the scope of freedom to operate?
Meropenem
is the generic ingredient in four branded drugs marketed by Acs Dobfar, Acs Dobfar Spa, Amneal Pharms, Brooks Steriscience, Daewoong Pharm Co, Eugia Pharma, Gland, Hospira Inc, Hq Spclt Pharma, Sandoz, Savior Lifetec Corp, Pfizer, B Braun Medical Inc, and Rempex, and is included in fifteen NDAs. There are seven patents protecting this compound. Additional information is available in the individual branded drug profile pages.There are thirty-two drug master file entries for meropenem. Thirteen suppliers are listed for this compound.
Summary for meropenem
| US Patents: | 7 |
| Tradenames: | 4 |
| Applicants: | 14 |
| NDAs: | 15 |
| Drug Master File Entries: | 32 |
| Finished Product Suppliers / Packagers: | 13 |
| Raw Ingredient (Bulk) Api Vendors: | 84 |
| Clinical Trials: | 131 |
| Patent Applications: | 7,455 |
| Formulation / Manufacturing: | see details |
| Drug Prices: | Drug price trends for meropenem |
| What excipients (inactive ingredients) are in meropenem? | meropenem excipients list |
| DailyMed Link: | meropenem at DailyMed |
Recent Clinical Trials for meropenem
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Antabio | Phase 1 |
| Wake Forest University Health Sciences | Phase 4 |
| Assistance Publique - Hôpitaux de Paris | Phase 4 |
Pharmacology for meropenem
| Drug Class | Penem Antibacterial |
US Patents and Regulatory Information for meropenem
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sandoz | MEROPENEM | meropenem | INJECTABLE;INJECTION | 091201-002 | Mar 29, 2011 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| Gland | MEROPENEM | meropenem | INJECTABLE;INJECTION | 206141-002 | Jun 8, 2016 | AP | RX | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | |||
| B Braun Medical Inc | MEROPENEM AND SODIUM CHLORIDE IN DUPLEX CONTAINER | meropenem | POWDER;INTRAVENOUS | 202106-002 | Apr 30, 2015 | RX | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| Rempex | VABOMERE | meropenem; vaborbactam | POWDER;INTRAVENOUS | 209776-001 | Aug 29, 2017 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | Y | Y | ⤷ Try a Trial | ||
| Rempex | VABOMERE | meropenem; vaborbactam | POWDER;INTRAVENOUS | 209776-001 | Aug 29, 2017 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
| Rempex | VABOMERE | meropenem; vaborbactam | POWDER;INTRAVENOUS | 209776-001 | Aug 29, 2017 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| Rempex | VABOMERE | meropenem; vaborbactam | POWDER;INTRAVENOUS | 209776-001 | Aug 29, 2017 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for meropenem
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Pfizer | MERREM | meropenem | INJECTABLE;INJECTION | 050706-001 | Jun 21, 1996 | ⤷ Try a Trial | ⤷ Try a Trial |
| Pfizer | MERREM | meropenem | INJECTABLE;INJECTION | 050706-003 | Jun 21, 1996 | ⤷ Try a Trial | ⤷ Try a Trial |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - HIPAA-ready chat for life sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
